These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 11914913

  • 1. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines.
    Pavillard V, Agostini C, Richard S, Charasson V, Montaudon D, Robert J.
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):329-35. PubMed ID: 11914913
    [Abstract] [Full Text] [Related]

  • 2. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants.
    Jansen WJ, Zwart B, Hulscher ST, Giaccone G, Pinedo HM, Boven E.
    Int J Cancer; 1997 Jan 27; 70(3):335-40. PubMed ID: 9033637
    [Abstract] [Full Text] [Related]

  • 3. Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells.
    Wu MH, Yan B, Humerickhouse R, Dolan ME.
    Clin Cancer Res; 2002 Aug 27; 8(8):2696-700. PubMed ID: 12171903
    [Abstract] [Full Text] [Related]

  • 4. Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance.
    Wierdl M, Wall A, Morton CL, Sampath J, Danks MK, Schuetz JD, Potter PM.
    Mol Pharmacol; 2003 Aug 27; 64(2):279-88. PubMed ID: 12869632
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
    van Ark-Otte J, Kedde MA, van der Vijgh WJ, Dingemans AM, Jansen WJ, Pinedo HM, Boven E, Giaccone G.
    Br J Cancer; 1998 Jun 27; 77(12):2171-6. PubMed ID: 9649129
    [Abstract] [Full Text] [Related]

  • 7. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan.
    Xu G, Zhang W, Ma MK, McLeod HL.
    Clin Cancer Res; 2002 Aug 27; 8(8):2605-11. PubMed ID: 12171891
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.
    Westover D, Ling X, Lam H, Welch J, Jin C, Gongora C, Del Rio M, Wani M, Li F.
    Mol Cancer; 2015 Apr 28; 14():92. PubMed ID: 25928015
    [Abstract] [Full Text] [Related]

  • 12. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
    Jensen NF, Agama K, Roy A, Smith DH, Pfister TD, Rømer MU, Zhang HL, Doroshow JH, Knudsen BR, Stenvang J, Brünner N, Pommier Y.
    J Exp Clin Cancer Res; 2016 Mar 31; 35():56. PubMed ID: 27029323
    [Abstract] [Full Text] [Related]

  • 13. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
    Erlichman C, Boerner SA, Hallgren CG, Spieker R, Wang XY, James CD, Scheffer GL, Maliepaard M, Ross DD, Bible KC, Kaufmann SH.
    Cancer Res; 2001 Jan 15; 61(2):739-48. PubMed ID: 11212277
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Regulation of carboxylesterase-2 expression by p53 family proteins and enhanced anti-cancer activities among 5-fluorouracil, irinotecan and doxazolidine prodrug.
    Xiao D, Yang D, Guo L, Lu W, Charpentier M, Yan B.
    Br J Pharmacol; 2013 Apr 15; 168(8):1989-99. PubMed ID: 23373735
    [Abstract] [Full Text] [Related]

  • 16. Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.
    Jandu H, Aluzaite K, Fogh L, Thrane SW, Noer JB, Proszek J, Do KN, Hansen SN, Damsgaard B, Nielsen SL, Stougaard M, Knudsen BR, Moreira J, Hamerlik P, Gajjar M, Smid M, Martens J, Foekens J, Pommier Y, Brünner N, Schrohl AS, Stenvang J.
    BMC Cancer; 2016 Jan 22; 16():34. PubMed ID: 26801902
    [Abstract] [Full Text] [Related]

  • 17. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.
    Sanghani SP, Quinney SK, Fredenburg TB, Davis WI, Murry DJ, Bosron WF.
    Drug Metab Dispos; 2004 May 22; 32(5):505-11. PubMed ID: 15100172
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
    Boyer J, McLean EG, Aroori S, Wilson P, McCulla A, Carey PD, Longley DB, Johnston PG.
    Clin Cancer Res; 2004 Mar 15; 10(6):2158-67. PubMed ID: 15041737
    [Abstract] [Full Text] [Related]

  • 20. Cellular parameters predictive of the clinical response of colorectal cancers to irinotecan. A preliminary study.
    Pavillard V, Charasson V, Laroche-Clary A, Soubeyran I, Robert J.
    Anticancer Res; 2004 Mar 15; 24(2B):579-85. PubMed ID: 15160997
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.